Jeff L Vacirca bought $501K of Caris Life Sciences (CAI)
Executed May 11, disclosed May 12, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 12), the stock returned +5.5% (delay-adjusted); from the execution session (May 11), +4.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jeff L Vacirca (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Caris Life Sciences, Inc. (CAI). Across 1 priced purchase filing, the average 21-session return was +4.8% from execution and +5.5% from disclosure (delay-adjusted; derived). The largest single filing was $501K of CAI (31,050 sh × $16.15, as filed), executed May 11.
Healthcare · Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and inter…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→